AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

NG004 in Incomplete Spinal Cord Injury Patients

RecruitingPhase 1Ages 18 Years - 75 YearsAllNovaGo Therapeutics AG
💬

In plain words

What the trial is, and whether it could suit you

This is a randomized, double-blind, placebo controlled, multicenter trial of NG004 in patients with acute traumatic incomplete cervical SCI. The trial will evaluate the safety and tolerability, PK, and effects on motor function and daily life functioning of NG004 compared with placebo.

Sign in to get the eligibility rules as simple questions to take to your doctor.

📋 Eligibility rules (as published)
Inclusion Criteria: * Acute incomplete cervical SCI (Neurological level of injury C1 ≤ lesion ≤ C8) with confirmed classification of American Spinal Injury Association (ASIA) impairment scale (AIS) B, C and D at Screening * 4-28 days post-injury and no earlier than 4 days after spinal surgery * No required mechanical ventilation or patients that do not completely depend on mechanical ventilation * Hemodynamically and clinical stable patient according to the acute SCI condition at baseline Exclusion Criteria: * Trauma caused by ballistic or other injury that directly penetrates the spinal cord including gunshot and knife wounds * Multiple levels of clinically relevant spinal cord lesions * Major brachial or lumbar plexus damage/trauma * Significant head trauma or other injury that was, in the opinion of the investigator, sufficient to interfere with the assessment of the spinal cord function * Other significant pre-existing or current severe systemic disease * History of or an episode of multiple sclerosis or Guillain-Barre syndrome * History of recent meningitis or meningoencephalitis * History of refractory epilepsy * Patients with uncontrolled bleeding diathesis and/or who require concomitant therapeutic anticoagulation and not related to SCI * Presence of any unstable medical or psychiatric condition * Drug dependence any time within the last 6 months before Screening * Pregnant or nursing women * History of a life-threatening allergic or immune-mediated reaction * Presence of infection around the location where the spinal needle insertions are planned for applying the intrathecal injections * Participation in any clinical investigation within 4 weeks prior to dosing or longer if required by local regulations * Patients who are unconscious
💊

What it tests

  • NG004
  • Placebo
📍

Where

10 sites
Klinik für Querschnittgelähmte, Klinikum Bayreuth
Bayreuth, Germany
BG Universitätsklinikum Bergmannsheil
Bochum, Germany
Zentrum für Rückenmarkverletzte und Klinik für Orthopädie, BG Klinikum Bergmannstrost
Halle, Germany
BG Klinikum Hamburg
Hamburg, Germany
Klinik für Paraplegiologie, Universitätsklinikum Heidelberg
Heidelberg, Germany
Zentrum für Rückenmarksverletzte, Unfallklinik Murnau
Murnau am Staffelsee, Germany
BG Klinik Tübingen
Tübingen, Germany
REHAB Basel
Basel, Switzerland

…and 2 more on ClinicalTrials.gov.

🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy